NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
Annual report [Section 13 and 15(d), not S-K Item 405]
Current report
Definitive proxy statements
View and filter by group or type
